Latest & greatest articles for asthma

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on asthma or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on asthma and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for asthma

281. Pulse oximeters to self monitor oxygen saturation levels as part of a personalised asthma action plan for people with asthma. (Abstract)

Pulse oximeters to self monitor oxygen saturation levels as part of a personalised asthma action plan for people with asthma. We became aware through talking with people with asthma that some are using pulse oximeters to monitor their own blood oxygen levels during an asthma attack. Pulse oximeters are marketed by some suppliers as essential equipment for the home medicine cabinet. We wanted to find out if reliable evidence is available on use of pulse oximeters to self monitor asthma (...) exacerbations at home. We decided to include only trials that used pulse oximeters as part of a personalised asthma action plan because it is important that decisions are made on the basis of symptoms as well as oxygen saturation, and that patients have a clear protocol to follow when their asthma worsens.To determine whether pulse oximeters used as part of a personalised asthma action plan for people with asthma are safer and more effective than a personalised asthma action plan alone.We searched

2015 Cochrane

282. Intravenous Magnesium Sulphate for Pre-Hospital Management of Refractory Asthma: Clinical Effectiveness and Guidelines

Intravenous Magnesium Sulphate for Pre-Hospital Management of Refractory Asthma: Clinical Effectiveness and Guidelines Intravenous Magnesium Sulphate for Pre-Hospital Management of Refractory Asthma: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Intravenous Magnesium Sulphate for Pre-Hospital Management of Refractory Asthma: Clinical Effectiveness and Guidelines Intravenous Magnesium Sulphate for Pre-Hospital Management of Refractory Asthma: Clinical (...) Effectiveness and Guidelines Published on: September 2, 2015 Project Number: RB0906-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of intravenous administration of magnesium sulphate for the treatment of acute and unrelieved, refractory asthma-related bronchospasm in prehospital settings? What are the evidence-based guidelines regarding the intravenous administration of magnesium sulphate for the treatment of acute

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

283. Bronchial Thermoplasty for Severe Asthma: A Review of the Clinical and Cost-Effectiveness, and Guidelines

, however three of the four identified guidelines conditionally recommended bronchial thermoplasty as a potential treatment option for poorly controlled, severely asthmatic patients already on optimal pharmacological therapy. Tags asthma, bronchoscopy, respiratory Files Rapid Response Summary with Critical Appraisal Published : August 27, 2015 Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter: (...) Bronchial Thermoplasty for Severe Asthma: A Review of the Clinical and Cost-Effectiveness, and Guidelines Bronchial Thermoplasty for Severe Asthma: A Review of the Clinical and Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Bronchial Thermoplasty for Severe Asthma: A Review of the Clinical and Cost-Effectiveness, and Guidelines Bronchial Thermoplasty for Severe Asthma: A Review of the Clinical and Cost-Effectiveness, and Guidelines Published on: August 27, 2015

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

284. Community Health Worker Home Visits for Medicaid-Enrolled Children With Asthma: Effects on Asthma Outcomes and Costs Full Text available with Trip Pro

Community Health Worker Home Visits for Medicaid-Enrolled Children With Asthma: Effects on Asthma Outcomes and Costs We sought to estimate the return on investment of a streamlined version of an evidence-based community health worker (CHW) asthma home visit program.We used a randomized parallel group trial of home visits by CHWs to Medicaid-enrolled children with uncontrolled asthma versus usual care.A total of 373 participants enrolled in the study (182 in the intervention group and 191 (...) in the control group, of whom 154 and 179, respectively, completed the study). The intervention group had greater improvements in asthma symptom-free days (2.10 days more over 2 weeks; 95% CI =  1.17, 3.05; P < .001) and caretakers' quality of life (0.43 units more; 95% CI = 0.20, 0.66; P < .001) and a larger reduction in urgent health care utilization events (1.31 events fewer over 12 months; 95% CI = -2.10, -0.52; P = .001). The intervention arm compared with the control arm saved $1340.92 for the $707.04

2015 EvidenceUpdates Controlled trial quality: uncertain

285. Mometasone Furoate (Asmanex Twisthaler) for asthma. It is inhaled, but does not aspire...for something more

Mometasone Furoate (Asmanex Twisthaler) for asthma. It is inhaled, but does not aspire...for something more 2015. DAR No 2: Mometasone Furoate. Asmanex Twisthaler® for asthma management - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DAR No 2: Mometasone Furoate. Asmanex Twisthaler® for asthma management DAR No 2: Mometasone Furoate. Asmanex Twisthaler® for asthma management Content tools Share it It is inhaled, but does not aspire (...) ...for something more Mometasone furoate is an inhaled glucocorticoid indicated in the maintenance treatment of persistent asthma. No advantage has been shown in terms of relevant clinical outcomes with respect to other inhaled corticosteroids. The profile of adverse effects and the administration regimen of mometasone are similar to that of other inhaled corticoids. Enviar comentario You can send us a comment or suggestion and we will respond to most frequently asked questions Competing interests (complete

2015 Drug and Therapeutics Bulletin of Navarre (Spain)

286. Sublingual immunotherapy for asthma. Full Text available with Trip Pro

Sublingual immunotherapy for asthma. Asthma is a common long-term respiratory disease affecting approximately 300 million people worldwide. Approximately half of people with asthma have an important allergic component to their disease, which may provide an opportunity for targeted treatment. Sublingual immunotherapy (SLIT) aims to reduce asthma symptoms by delivering increasing doses of an allergen (e.g. house dust mite, pollen extract) under the tongue to induce immune tolerance. However (...) as of 25 March 2015.We included parallel randomised controlled trials (RCTs), irrespective of blinding or duration, that evaluated sublingual immunotherapy versus placebo or as an add-on to standard asthma management. We included both adults and children with asthma of any severity and with any allergen-sensitisation pattern. We included studies that recruited participants with asthma, rhinitis, or both, providing at least 80% of trial participants had a diagnosis of asthma.Two review authors

2015 Cochrane

287. Bronchial thermoplasty for the treatment of severe persistent asthma

Bronchial thermoplasty for the treatment of severe persistent asthma Bronchial thermoplasty for the treatment of severe persistent asthma Bronchial thermoplasty for the treatment of severe persistent asthma Medical Services Advisory Committee Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Medical Services Advisory Committee. Bronchial thermoplasty (...) for the treatment of severe persistent asthma. Canberra: Medical Services Advisory Committee (MSAC). MSAC application 1384. 2015 Authors' objectives Bronchial thermoplasty (BT) is performed in a bronchoscopy/endoscopy suite and takes about an hour to complete each of the three required treatments. BT is usually conducted under moderate sedation. Post-procedure, patients are observed and monitored for approximately 2-4 hours. Authors' conclusions After considering the available evidence presented in relation

2015 Health Technology Assessment (HTA) Database.

288. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma. Full Text available with Trip Pro

Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma. Long-acting muscarinic antagonists (LAMA), a class of drugs with proven effectiveness in chronic obstructive pulmonary disease (COPD), are being considered as an add-on option for adults with asthma whose condition is uncontrolled on inhaled corticosteroids (ICS). It is important to assess the safety and efficacy of LAMA add-on as an alternative to the prolonged use (...) of higher doses of ICS, which are known to cause undesirable side effects in some people.To compare the effects of adding a LAMA to any dose of ICS versus increasing the dose of ICS, for uncontrolled asthma in adults.We searched the Cochrane Airways Group Specialised Register (CAGR) from its inception in 1995 to April 2015, imposing no restriction on language of publication. We also handsearched trial registries, reference lists of primary studies and existing reviews, as well as manufacturers

2015 Cochrane

289. Nebulised budesonide using a novel device in patients with oral steroid-dependent asthma Full Text available with Trip Pro

Nebulised budesonide using a novel device in patients with oral steroid-dependent asthma This phase 2/3 randomised, parallel-group, placebo-controlled trial investigated oral corticosteroid (OCS)-sparing efficacy, safety and tolerability of nebulised budesonide (Bud) administered with a novel computer-controlled, compressor-driven inhalation system (AKITA) as add-on therapy to Global Initiative for Asthma step 5. Patients (18-65 years) with OCS-dependent asthma were randomised (2:1:1:1 (...) forced expiratory volume in 1 s improved (from baseline to week 18) for AICS-Bud 1 mg (239±460 mL, p<0.001) and AICS-Bud 0.5 mg (126±345 mL, p=0.01) but not placebo (93±419 mL, p=0.36) or CN-Bud (137±459 mL, p=0.18). Fewer AICS-Bud 1 mg-treated patients experienced asthma exacerbations (7.5%) compared with placebo (17.5%) or CN-Bud (22.5%). All treatments were well tolerated. Budesonide applied with AKITA allowed significant meaningful OCS reduction in OCS-dependent asthma patients while improving

2015 EvidenceUpdates Controlled trial quality: predicted high

290. Effect of a soy isoflavone supplement on lung function and clinical outcomes in patients with poorly controlled asthma: a randomized clinical trial. Full Text available with Trip Pro

Effect of a soy isoflavone supplement on lung function and clinical outcomes in patients with poorly controlled asthma: a randomized clinical trial. Soy isoflavone supplements are used to treat several chronic diseases, although the data supporting their use are limited. Some data suggest that supplementation with soy isoflavone may be an effective treatment for patients with poor asthma control.To determine whether a soy isoflavone supplement improves asthma control in adolescent and adult (...) patients with poorly controlled disease.Multicenter, randomized, double-blind, placebo-controlled trial conducted between May 2010 and August 2012 at 19 adult and pediatric pulmonary and allergy centers in the American Lung Association Asthma Clinical Research Centers network. Three hundred eighty-six adults and children aged 12 years or older with symptomatic asthma while taking a controller medicine and low dietary soy intake were randomized, and 345 (89%) completed spirometry at week 24.Participants

2015 JAMA Controlled trial quality: predicted high

291. Stopping long-acting beta2-agonists (LABA) for children with asthma well controlled on LABA and inhaled corticosteroids. Full Text available with Trip Pro

Stopping long-acting beta2-agonists (LABA) for children with asthma well controlled on LABA and inhaled corticosteroids. Asthma is the most common chronic medical condition among children and is one of the most common causes of hospitalisation and medical visits. Poorly controlled asthma often leads to preventable exacerbations that require additional medications, hospital stays, or treatment in the emergency department.Long-acting beta2-agonists (LABA) are the preferred add-on treatment (...) for children with asthma whose symptoms are not well controlled on inhaled corticosteroids (ICS). The US Food and Drug Administration has issued a 'black box' warning for LABA in asthma, and now recommends that they be used "for the shortest duration of time required to achieve control of asthma symptoms and discontinued, if possible, once asthma control is achieved".To compare the effect on asthma control and adverse effects of stepping down to inhaled corticosteroids (ICS)-only therapy versus continuing

2015 Cochrane

292. Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. Full Text available with Trip Pro

Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. The most prevalent phenotype of asthma is characterized by eosinophil-dominated inflammation that is driven by a type 2 helper T cell (Th2). Therapeutic targeting of GATA3, an important transcription factor of the Th2 pathway, may be beneficial. We evaluated the safety and efficacy of SB010, a novel DNA enzyme (DNAzyme) that is able to cleave and inactivate GATA3 messenger RNA (mRNA).We conducted a randomized, double (...) -blind, placebo-controlled, multicenter clinical trial of SB010 involving patients who had allergic asthma with sputum eosinophilia and who also had biphasic early and late asthmatic responses after laboratory-based allergen provocation. A total of 40 patients could be evaluated; 21 were assigned to receive 10 mg of SB010, and 19 were assigned to receive placebo, with each study drug administered by means of inhalation once daily for 28 days. An allergen challenge was performed before and after

2015 NEJM Controlled trial quality: predicted high

294. Omalizumab Treatment for Adults and Children with Allergic Asthma

Omalizumab Treatment for Adults and Children with Allergic Asthma Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered (...) with Allergic Asthma: A Review of the Clinical Effectiveness, Cost-Effectiveness, and Guidelines DATE: 9 March 2015 CONTEXT AND POLICY ISSUES Asthma is chronic inflammatory disease of the airways that affects 300 million individuals worldwide and is associated with significant mortality and morbidity. 1 Allergic asthma is the most common form of asthma, where exacerbations are triggered by allergens such as dust mites and pollen and are attributable to immunoglobulin E (IgE)-mediated mechanisms. 2 Asthma

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

295. Multidimensional endotypes of asthma: topological data analysis of cross-sectional clinical, pathological, and immunological data. (Abstract)

Multidimensional endotypes of asthma: topological data analysis of cross-sectional clinical, pathological, and immunological data. Incomplete understanding of mechanisms and clinicopathobiological heterogeneity in asthma hinders research progress. Pathogenic roles for T-helper-type 17 (Th17) cells and invariant T cells implied by murine data have yet to be assessed in man. We aimed to investigate the role of Th17 and mucosal associated invariant T (MAIT) cells in airway inflammation (...) ; to characterise associations between diverse clinical and immunological features of asthma; and to identify novel multidimensional asthma endotypes.In this single-centre, cross-sectional observational study in the UK, we assessed volunteers with mild-to-severe asthma and healthy non-atopic controls using clinical and physiological assessment and immunological sampling of blood, induced sputum, endobronchial biopsy, and bronchoalveolar lavage for flow cytometry and multiplex-electrochemiluminescence assays

2015 Lancet

296. Eczema and indoor environment: lessons from the International Study of Asthma and Allergies in Childhood (ISAAC) Phase 2. (Abstract)

Eczema and indoor environment: lessons from the International Study of Asthma and Allergies in Childhood (ISAAC) Phase 2. Numerous studies have reported a positive association between damp housing conditions and asthma, but little is known about indoor environmental exposures in relation to childhood eczema. We aimed to specifically investigate the effect of indoor mould and dampness on eczema risk in the International Study of Asthma and Allergies in Childhood (ISAAC).ISAAC Phase 2 is a cross

2015 Lancet

297. Asthma and Exercise-Induced Bronchoconstriction in Athletes. Full Text available with Trip Pro

Asthma and Exercise-Induced Bronchoconstriction in Athletes. 25671256 2015 02 18 2015 02 12 1533-4406 372 7 2015 Feb 12 The New England journal of medicine N. Engl. J. Med. Asthma and exercise-induced bronchoconstriction in athletes. 641-8 10.1056/NEJMra1407552 Boulet Louis-Philippe LP O'Byrne Paul M PM eng Journal Article Review United States N Engl J Med 0255562 0028-4793 0 Anti-Asthmatic Agents AIM IM Anti-Asthmatic Agents therapeutic use Asthma diagnosis drug therapy etiology Asthma

2015 NEJM

298. Association between asthma and risk of developing obstructive sleep apnea. Full Text available with Trip Pro

Association between asthma and risk of developing obstructive sleep apnea. Obstructive sleep apnea (OSA) is more common among patients with asthma; whether asthma is associated with the development of OSA is unknown.To examine the prospective relationship of asthma with incident OSA.Population-based prospective epidemiologic study (the Wisconsin Sleep Cohort Study) beginning in 1988. Adult participants were recruited from a random sample of Wisconsin state employees to attend overnight (...) polysomnography studies at 4-year intervals. Asthma and covariate information were assessed during polysomnography studies through March 2013. Eligible participants were identified as free of OSA (apnea-hypopnea index [AHI] of <5 events/h and not treated) by 2 baseline polysomnography studies. There were 1105 4-year follow-up intervals provided by 547 participants (52% women; mean [SD] baseline age, 50 [8] years).Questionnaire-assessed presence and duration of self-reported physician-diagnosed asthma.The

2015 JAMA

299. Management of an Acute Asthma Attack in Adults (aged 16 years and older)

Guidelines Network (SIGN), Edinburgh, Scotland for use of the sections of the BTS SIGN Asthma Guidelines included in this document; and in addition, I would also like to thank Suzanne Hurd and Board of GINA (Global Initiative on Asthma) for access to use of sections of GINA guidelines on asthma. _______________________________________ Prof Pat Manning Chairperson - Guideline Development Group Clinical Lead, National Clinical Programme for AsthmaTable of Contents Section 1: Background 7 1.1 Need (...) Management of an Acute Asthma Attack in Adults (aged 16 years and older) Management of an Acute Asthma Attack in Adults (aged 16 years and older) National Clinical Guideline No. 14 November 2015Guideline Development Group The National Clinical Guideline on Management of an Acute Asthma Attack in Adults was developed by a sub-group of the National Clinical Programme for Asthma (NCPA). The Guideline Development Group was chaired by Professor Pat Manning. Using this National Clinical Guideline

2015 National Clinical Guidelines (Ireland)

300. Is Dexamethasone as Effective as Prednisone or Prednisolone in the Management of Pediatric Asthma Exacerbations?

likely to vomit both in the ED (relative risk [RR] 0.29; 95% CI 0.12 to 0.69) and at home (RR 0.32; 95% CI 0.14 to 0.74) compared with pa- tients who received prednisone/ prednisolone. A recent study of pedi- atric asthma patients demonstrated that greater adherence to medications was associated with a lower likeli- hood of asthma-related ED visits. 6 In addition, convenience has been identi?ed as a leading factor affecting adherence in asthmatic patients. 7 Despite the limitations of this systematic (...) Is Dexamethasone as Effective as Prednisone or Prednisolone in the Management of Pediatric Asthma Exacerbations? Systematic Review Snapshot TAKE-HOME MESSAGE The use of 1 to 2 doses of dexamethasone for acute pediatric asthma exacerbation does not appear to increase the frequency of unscheduled return visits compared with a 5-day course of prednisone or prednisolone. Is Dexamethasone as Effective as Prednisone or Prednisolone in the Management of Pediatric Asthma Exacerbations? EBEM

2015 Annals of Emergency Medicine Systematic Review Snapshots